Summary & Overview
HCPCS Q0245: Bamlanivimab and Etesevimab Injection, 2100 mg
HCPCS Level II code Q0245 designates the combined monoclonal antibody product bamlanivimab and etesevimab at a 2100 mg dose for therapeutic injection. This code matters nationally because monoclonal antibody therapies have been a key component of outpatient COVID-19 treatment strategies, affecting hospital capacity, outpatient infusion services, and payer coverage policies. Q0245 standardizes billing for this specific product and dose, enabling consistent claims processing and utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing modifiers, and how this service typically maps to outpatient infusion sites. The publication summarizes benchmarks and policy considerations relevant to providers and revenue cycle staff, outlines clinical context for monoclonal antibody administration, and highlights documentation and coding elements tied to this HCPCS Level II code.
The report provides practical benchmarks for service lines that deliver infusion therapies, notes common payer interactions, and synthesizes clinically relevant information for coding teams. Data not available in the input is indicated where applicable.
Billing Code Overview
HCPCS Level II code Q0245 represents Injection, bamlanivimab and etesevimab, 2100 mg. This code describes a combined monoclonal antibody infusion product used for passive immunotherapy against SARS-CoV-2. The service type is therapeutic monoclonal antibody infusion/injection, delivered as a single administration of the specified drug combination and dose.
The typical site of service for Q0245 is outpatient infusion settings, including hospital outpatient departments, ambulatory infusion centers, and other clinic-based infusion suites where intravenous or subcutaneous monoclonal antibody therapies are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with recently diagnosed mild-to-moderate COVID-19 who is at high risk for progression to severe disease (for example, older age, obesity, diabetes, chronic kidney disease, immunosuppression, or cardiovascular disease). The patient tests positive for SARS-CoV-2 and within the authorized treatment window presents to an outpatient infusion center, emergency department infusion unit, or hospital-based infusion clinic for monoclonal antibody therapy.
The clinical workflow includes verification of authorization and payer coverage, review of eligibility including symptom onset date and risk factors, informed consent, baseline vital signs and documentation of oxygenation status, preparation and administration of the intravenous infusion of Q0245 (bamlanivimab and etesevimab, 2100 mg), observation for infusion-related reactions for the recommended monitoring period, and documentation of medication lot numbers, dosing, and any immediate adverse events. Billing uses the HCPCS Level II code Q0245 for the drug; common modifiers such as 78 (return to the operating/procedure room for a related procedure during the postoperative period) and SH (specific to facility identification for certain programs) may be appended per payer requirements.
Typical sites of service include outpatient infusion centers, hospital outpatient departments, emergency department infusion areas, and skilled nursing facilities capable of delivering monitored IV therapy. Patient education includes signs of infusion reaction and instructions for follow-up if symptoms progress.
Coding Specifications
| Modifier |
|---|